A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM, Zonneville J, Naranjo MN, Serio H, Melendy T, Straubinger RM, Gillard B, Foster BA, Rajan P, Attwood K, Chatley S, Iyer R, Fountzilas C, Bakin AV.
Alruwaili MM, et al. Among authors: naranjo mn.
Cell Rep Med. 2024 Mar 19;5(3):101434. doi: 10.1016/j.xcrm.2024.101434. Epub 2024 Feb 21.
Cell Rep Med. 2024.
PMID: 38387463
Free PMC article.